vosoritide
Orphan Drug Cold Chain RequiredFDA Approved
Description
Vosoritide is a biologic analog of C-type natriuretic peptide (CNP) designed to promote bone growth by stimulating endochondral ossification. It is approved for the treatment of achondroplasia in pediatric patients aged 5 years and older with open epiphyses. While SADDAN is a severe form related to FGFR3 mutations similar to achondroplasia, vosoritide's mechanism may have theoretical relevance, though it is not specifically approved for SADDAN.
Indications & Therapeutic Use
achondroplasia in pediatric patients with open epiphyses
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
vosoritide
| Generic Name | vosoritide |
| Brands | 1 brand available |
| Active Ingredient | vosoritide |
| Drug Class | achondroplasia in pediatric patients with open epiphyses |
| Manufacturer | BioMarin Pharmaceutical |
| Dosage Forms | subcutaneous injection, 0.4mg, 0.56mg, 1.2mg vials |
| Medical Code | M09AX09 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 21 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT03197766 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes